Company Valuation: Trident Texofab Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2021 2022 2023 2024 2025 2026
Market Cap 1 259.3 623.3 579.4 491.6 2,370 687.1
Change - 140.39% -7.04% -15.15% 382.09% -71.01%
Enterprise Value (EV) 1 612 1,029 959.4 891.2 2,635 1,053
Change - 68.18% -6.79% -7.11% 195.66% -60.03%
P/E 73.6x 63.4x 26.2x 45.6x 83.6x 96.1x
PBR 2.17x 4.81x 3.82x 3.02x 5.02x 1.24x
PEG - 0x 0x -0.9x 0.9x -1.2x
Capitalization / Revenue 0.52x 0.74x 0.6x 0.49x 1.94x 0.58x
EV / Revenue 1.23x 1.22x 1x 0.9x 2.16x 0.89x
EV / EBITDA 20.1x 17.7x 11.9x 11.5x 49.3x 21.2x
EV / EBIT 27.7x 22.7x 14.6x 14.3x 68.9x 30.1x
EV / FCF -7.07x -16.8x 52.8x -57.5x -14x -8.48x
FCF Yield -14.1% -5.96% 1.9% -1.74% -7.13% -11.8%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 0.35 0.9759 2.2 1.07 2.09 0.4767
Distribution rate - - - - - -
Net sales 1 499.3 842.9 963.6 994.8 1,221 1,180
EBITDA 1 30.47 58.21 80.81 77.71 53.4 49.74
EBIT 1 22.11 45.31 65.66 62.54 38.24 34.96
Net income 1 3.532 9.827 22.18 10.8 25.1 7.046
Net Debt 1 352.7 405.9 380 399.6 264.9 366
Reference price 2 25.75 61.90 57.54 48.82 174.80 45.82
Nbr of stocks (in thousands) 10,070 10,070 10,070 10,070 13,559 14,996
Announcement Date 8/25/21 8/31/22 8/28/23 9/3/24 9/1/25 9/8/26
1INR in Million2INR
Estimates


P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 2.52M
35.34x4.83x23.69x0.53% 3.92B
9.44x0.54x5.72x3.81% 3.86B
34.15x1.95x15.92x - 2.14B
14.23x1.72x7.27x3.16% 2.13B
10.12x - - 5.82% 1.8B
10.96x - - 7.92% 1.55B
12.28x1.4x9.13x1.32% 1.54B
Average 18.07x 2.09x 12.35x 3.76% 2.12B
Weighted average by Cap. 19.62x 2.28x 13.14x 3.26%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Trident Texofab Limited

Historical PBR trend

Valuation ratios - PBR - Trident Texofab Limited

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Trident Texofab Limited

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Trident Texofab Limited

  1. Stock Market
  2. Stocks
  3. TTFL6 Stock
  4. Valuation Trident Texofab Limited